Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameEverest Med
Stock Code01952
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家生物製藥公司,業務包括潛在全球同類首創或同類最佳療法的許用、臨床開發及商業化,以解決大中華及亞太區其他新興市場尚未得到滿足的醫療需要。
Listing Date2020-10-09
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市南京西路1266號上海恒隆廣場辦公樓1號樓6601–6606室
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteeverestmedicines.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 55.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 27,500
Par ValueTo be extracted
Offer Period2020-09-25 to 2020-09-30
Global Offering Shares63,547,000 shares
HK Public Offer Shares (Initial)6,355,000 shares (10.0%)
Public Offer Lots (Initial)12,710lots (Pool A6,355lots,Pool B6,355lots)
International Placing Shares (Initial)57,192,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO283,690,389 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,495,085,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 27,500
2 lots 1,000 HK$ 55,000
3 lots 1,500 HK$ 82,500
4 lots 2,000 HK$ 110,000
5 lots 2,500 HK$ 137,500
6 lots 3,000 HK$ 165,000
7 lots 3,500 HK$ 192,500
8 lots 4,000 HK$ 220,000
9 lots 4,500 HK$ 247,500
10 lots 5,000 HK$ 275,000
12 lots 6,000 HK$ 330,000
14 lots 7,000 HK$ 385,000
16 lots 8,000 HK$ 440,000
18 lots 9,000 HK$ 495,000
20 lots 10,000 HK$ 550,000
30 lots 15,000 HK$ 825,000
40 lots 20,000 HK$ 1,100,000
50 lots 25,000 HK$ 1,375,000
60 lots 30,000 HK$ 1,650,000
70 lots 35,000 HK$ 1,925,000
80 lots 40,000 HK$ 2,200,000
90 lots 45,000 HK$ 2,475,000
100 lots 50,000 HK$ 2,750,000
120 lots 60,000 HK$ 3,300,000
140 lots 70,000 HK$ 3,850,000
160 lots 80,000 HK$ 4,400,000
180 lots 90,000 HK$ 4,950,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
200 lots 100,000 HK$ 5,500,000
300 lots 150,000 HK$ 8,250,000
400 lots 200,000 HK$ 11,000,000
500 lots 250,000 HK$ 13,750,000
600 lots 300,000 HK$ 16,500,000
700 lots 350,000 HK$ 19,250,000
800 lots 400,000 HK$ 22,000,000
900 lots 450,000 HK$ 24,750,000
1,000 lots 500,000 HK$ 27,500,000
1,200 lots 600,000 HK$ 33,000,000
1,400 lots 700,000 HK$ 38,500,000
1,600 lots 800,000 HK$ 44,000,000
1,800 lots 900,000 HK$ 49,500,000
2,000 lots 1,000,000 HK$ 55,000,000
3,000 lots 1,500,000 HK$ 82,500,000
4,000 lots 2,000,000 HK$ 110,000,000
5,000 lots 2,500,000 HK$ 137,500,000
6,355 lots 3,177,500 HK$ 174,762,500

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 11.05B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 15,602,971,395
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣176.1百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019-11
Other income and gains, net 0514
Administrative expenses -15,417-107,756
Operating profit -22,096-131,132
Net finance costs 0-170,190
Profit before tax -22,096-301,322
Income tax expense 00
Profit for the year -22,096-301,322
Balance Sheet
Item 20182019-11
Cash and cash equivalents 34,28198,442
Total current assets 34,281199,468
Total assets 102,913867,299
Total current liabilities 124,842296,071
Total liabilities 124,8421,193,917
Total equity -21,929-326,618
Cash Flow Statement
Item 20182019-11
Net cash from operating activities -202-168,875
Net cash from investing activities -69,156-655,498
Net cash from financing activities 103,734884,757
Net increase in cash 34,28164,161
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 72.75
First Day OpenHK$ 70.55
First Day Change32.27%
First Day Volume42603100.0
First Day Turnover3078790000.0
Use of Proceeds
1、60%或約1,970.4百萬港元用于我們的四款支柱產品; 2、15%或約492.6百萬港元用于為我們管線中其他候選藥物的進行中及計劃臨床試驗、登記備案準備及潛在商業化提供資金; 3、15%或約492.6百萬港元用于為我們的業務發展活動及擴展藥品管線提供資金; 4、10%或約328.4百萬港元用作營運資金以及一般及行政用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198
Overall Coordinators (5)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 Nomura International (Hong Kong) Limited CE AAF742 Brocade River Asset Management Limited CE BNR589
Joint Lead Managers (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Merrill Lynch (Asia Pacific) Limited CE AAC198 Citigroup Global Markets Asia Limited CE AAA137 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 Nomura International (Hong Kong) Limited CE AAF742 Brocade River Asset Management Limited CE BNR589

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 BlackRock Funds 116,242,500 HKD — 3.33% — 6 months 2021-04-09
2 C-Bridge IV Investment Sixteen Limited 232,485,000 HKD — 6.65% — 6 months 2021-04-09
3 Citadel Multi-Strategy Equities Master Fund Ltd. 38,747,500 HKD — 1.11% — 6 months 2021-04-09
4 Cormorant Asset Management, LP 77,495,000 HKD — 2.22% — 6 months 2021-04-09
5 GIC Private Limited 154,990,000 HKD — 4.43% — 6 months 2021-04-09
6 Hillhouse Funds 77,495,000 HKD — 2.22% — 6 months 2021-04-09
7 Indus Pacific Opportunities Master Fund, Ltd. 38,747,500 HKD — 1.11% — 6 months 2021-04-09
8 Invus Public Equities, L.P. 77,495,000 HKD — 2.22% — 6 months 2021-04-09
9 Janchor Partners Pan-Asian Master Fund 232,485,000 HKD — 6.65% — 6 months 2021-04-09
10 Lake Bleu Prime Healthcare Master Fund Limited 77,495,000 HKD — 2.22% — 6 months 2021-04-09
11 Octagon Investments Master Fund LP 38,747,500 HKD — 1.11% — 6 months 2021-04-09
12 OrbiMed Funds 77,495,000 HKD — 2.22% — 6 months 2021-04-09
13 RA Capital Healthcare Fund, L.P. 348,727,500 HKD — 9.98% — 6 months 2021-04-09
14 Rock Springs Capital Master Fund LP 77,495,000 HKD — 2.22% — 6 months 2021-04-09
15 Tybourne Equity Master Fund 38,747,500 HKD — 1.11% — 6 months 2021-04-09
16 Woodline Master Fund LP 38,747,500 HKD — 1.11% — 6 months 2021-04-09

Directors & Management

PositionChinese nameEnglish Name
Chairman傅唯—
Company Secretary印茵、劉綺華—
No director data available.

Major Shareholders

Major Shareholders & Holdings傅唯先生(信託受益人及信託創立人)持有127,645,215股,佔約44.99%;C-Bridge Investment Everest Limited持有50,000,000股,佔約17.62%;C-Bridge IV Investment Two Limited持有38,362,045股,佔約13.52%;C-Bridge Healthcare Fund II, L.P.等受控法團權益持有50,000,000股,佔約17.62%。
About this page

This page shows Everest Med (01952) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect